1379P Margetuximab (M) with Retifanlimab (R) in HER2+, PD-L1+ 1St-Line Unresectable/metastatic Gastroesophageal Adenocarcinoma (GEA): MAHOGANY Cohort A
Annals of Oncology(2021)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined